Respirerx Pharma - RSPI STOCK NEWS

RespireRx Pharmaceuticals Inc. (OTC Markets: RSPI) announced the publication of four studies detailing the pharmacological effects of new structural analogs of its lead compound, KRM-II-81. These analogs enhance GABAergic neurotransmission and show promise as anti-seizure agents without sedation. The studies demonstrated that KRM-II-81 effectively addresses epilepsy and pain without developing tolerance. Notably, the analog MP-III-024 proved effective in tremor models related to Parkinson's Disease. The company's focus on advancing KRM-II-81's development aims to facilitate upcoming human studies, potentially leading to breakthrough treatments for conditions lacking adequate therapies.

RespireRx Pharmaceuticals Inc. (OTC: RSPI) announced on March 22, 2023, the appointment of Joseph Siegelbaum as an independent director of its Board. Siegelbaum, previously a partner at Goodwin Procter LLP, brings extensive legal experience and a strong background in nonprofit leadership. Executive Chairman Dr. Lippa expressed confidence that Siegelbaum's expertise will enhance the Board's effectiveness. RespireRx focuses on developing treatments for psychiatric and neurological disorders, including a promising pipeline targeting obstructive sleep apnea and ADHD. The company continues to advance its innovative drug platforms with no approved treatments currently available for these conditions.

On March 1, 2023, ResolutionRx, a wholly-owned subsidiary of RespireRx Pharmaceuticals (OTC: RSPI), announced a services agreement with iNGENu CRO Pty Ltd for clinical research focused on a proprietary dronabinol formulation aimed at treating obstructive sleep apnea and anorexia. The agreement requires an initial deposit of US$50,000, part of a total R&D budget of approximately US$16.5 million. Notable developments include the formation of ResolutionRx, entry into financing arrangements with Radium Capital for R&D tax credits, and plans for further research activities in Australia. The company aims to commence clinical studies pending adequate financing and regulatory approvals.

RespireRx Pharmaceuticals (OTC: RSPI) announced a Letter of Intent and Term Sheet between its wholly-owned subsidiary ResolutionRx Ltd and Radium Capital on January 27, 2023. This partnership aims to establish financing arrangements to access research and development tax credits in Australia. The R&D Tax Incentive could provide ResolutionRx with a 43.5% tax refund to support its efforts in commercializing dronabinol for obstructive sleep apnea treatment. The total budget for this initiative is approximately $16.5 million, with a significant portion expected to qualify for the R&D tax refund.

RespireRx Pharmaceuticals Inc. (OTC Markets: RSPI) announced a significant amendment to its Exclusive License Agreement with the University of Illinois. The changes, effective December 15, 2022, include the elimination of $100,000 annual payments and a reduction of $200,000 in unpaid dues for 2021 and 2022. Future obligations are adjusted, with a $10,000 payment due after the first patient doses in Phase II, among other modifications. The agreement extension includes a 4% royalty on net sales for up to eight years post-patent expiration, increasing minimum payments to $350,000 upon FDA approval. This aims to streamline financial liabilities and enhance drug development focus.

RespireRx Pharmaceuticals Inc. (OTC Markets: RSPI) has established a wholly-owned subsidiary, ResolutionRx Ltd, in Australia to develop compounds targeting the endocannabinoid system, particularly dronabinol for obstructive sleep apnea (OSA). This initiative aims to leverage Australia’s research and development tax credit, potentially refunding 43.5% of eligible expenditures. ResolutionRx is pursuing equity financing and plans to list on the Australian Stock Exchange. The company is also collaborating with a contract research organization to conduct clinical studies on dronabinol, which has shown promise in earlier trials.

RespireRx Pharmaceuticals Inc. (OTC Markets: RSPI) has been accepted into the NIH HEAL Initiative's NINDS Preclinical Screening Platform for Pain program. The company’s lead GABAkine, KRM-II-81, has shown potential in relieving acute, chronic, and neuropathic pain without common opioid-related side effects. KRM-II-81 has exhibited notable analgesic activity in preclinical studies, comparable to traditional analgesics. The initiative aims to advance solutions to the opioid crisis, highlighting the significance of RespireRx's innovative pain management approach.

RespireRx Pharmaceuticals Inc. (OTC Pink Market: RSPI) announced the signing of a letter of intent with an Australian clinical research organization on November 14, 2022. This LOI initiates a contract process for comprehensive CRO services related to clinical studies of dronabinol aimed at treating obstructive sleep apnea (OSA). The projected budget for the studies is about $17 million. The LOI may lead to the formation of an Australian subsidiary, ResolutionRx, to manage research activities and access funding options, including a tax credit program, though no assurances can be made regarding future financing.

RespireRx Pharmaceuticals Inc. (OTCQ:RSPI) announces Jeff Margolis, CFO, will present at the Investor Summit Q4 in New York on November 14, 2022. The event will feature a group presentation and individual meetings. RespireRx focuses on developing innovative treatments for psychiatric and neurological disorders, utilizing drug platforms including neuromodulators like AMPAkines and pharmaceutical cannabinoids. Their research targets ADHD, spinal cord injury, and obstructive sleep apnea, with a promising portfolio in clinical development.